Impact of Solute Carrier Transporters in Glioma Pathology: A Comprehensive Review

Abstract

Solute carriers (SLCs) are essential for brain physiology and homeostasis due to their role in transporting necessary substances across cell membranes. There is an increasing need to further unravel their pathophysiological implications since they have been proposed to play a pivotal role in brain tumor development, progression, and the formation of the tumor microenvironment (TME) through the upregulation and downregulation of various amino acid transporters. Due to their implication in malignancy and tumor progression, SLCs are currently positioned at the center of novel pharmacological targeting strategies and drug development. In this review, we discuss the key structural and functional characteristics of the main SLC family members involved in glioma pathogenesis, along with their potential targeting options to provide new opportunities for CNS drug design and more effective glioma management.

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

“… 81 , 82 Angiogenic factors are particularly active in glioma TME, including transforming growth factor beta, hypoxia‐inducible factor, cyclooxygenase‐2, fibroblast growth factor, and helper T cell 2 cytokines. 83 , 84 Inhibition of the production of angiogenic factors, especially in glioma TME, and blocking the blood supply to the tumor are targets of action of many antiangiogenic agents.…”

Migration-Associated Transportome and Therapeutic Potential in Glioblastoma Multiforme (GBM)

“…The SLCs, therefore, are involved in many biological processes, including cell migration. Dysregulation of SLCs can disrupt these processes and lead to impaired cell migration, which can have significant implications including cancer progression [ 19 , 20 ]. To advance understanding of the genetic programs regulating cell migration in GBM cells, the study by Brosch P.K.…”